Repositioning Candidate Details
| Candidate ID: | R0765 |
| Source ID: | DB05305 |
| Source Type: | investigational |
| Compound Type: | biotech |
| Compound Name: | Cintredekin besudotox |
| Synonyms: | Cintredekin besudotox |
| Molecular Formula: | -- |
| SMILES: | -- |
| DrugBank Description: | Cintredekin besudotox has been developed as a specific tumor-targeting agent, which is administered by positive-pressure convection-enhanced delivery (CED) directly to brain tissue at risk for residual infiltrating glioblastoma multiforme (GBM) after tumor resection. Cintredekin besudotox is made from a human protein, Interleukin 13 (IL13), linked to a bacterial toxin, _Pseudomonas exotoxin_ (PE). The IL13 portion binds to receptors on the tumor. |
| CAS Number: | 372075-36-0 |
| Molecular Weight: | |
| DrugBank Indication: | Investigated for use/treatment in brain cancer. |
| DrugBank Pharmacology: | -- |
| DrugBank MoA: | A recombinant chimeric protein with potent antitumor activity. Cintredekin besudotox is composed of interleukin-13 (IL13), a pleiotropic immunoregulatory cytokine, linked to a mutated form of pseudomonas exotoxin A; this agent targets and kills tumor cells that express the IL13 receptor (IL13R). The IL13 moiety attaches to the IL13R on the tumor cell membrane, facilitating the entry of the exotoxin. The exotoxin moiety induces caspase-mediated apoptosis of tumor cells via a mechanism involving mitochondrial damage; it also catalyzes the transfer of ADP ribose from nicotinamide adenine dinucleotide (NAD) to elongation factor-2 in eukaryotic cells, thereby inactivating elongation factor 2 and inhibiting protein synthesis. |
| Targets: | Interleukin-13 |
| Inclusion Criteria: | Therapeutic strategy associated |
